<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Beta-adrenoreceptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> experimentally reduce cardiac and renal injury after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and are also clinically useful for <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and severe burns </plain></SENT>
<SENT sid="1" pm="."><plain>In addition, beta-adrenoreceptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> provide neuroprotective effects after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in experimental settings </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted the present study to compare the neuroprotective effects of several beta-adrenoreceptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> in rat transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="2" ids="5615">Halothane</z:chebi>-anesthetized normothermic adult male Sprague-Dawley rats were subjected to 2 h of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> using the intraluminal suture technique confirmed by laser Doppler flowmetry </plain></SENT>
<SENT sid="4" pm="."><plain>Rats received an IV infusion of saline 0.5 mL/h, <z:chebi fb="2" ids="8499">propranolol</z:chebi> 100 microg x kg(-1) x min(-1), <z:chebi fb="0" ids="3441">carvedilol</z:chebi> 4 microg x kg(-1) x min(-1), esmolol 200 microg x kg(-1) x min(-1), or landiolol 50 microg x kg(-1) x min(-1) (n = 6 in each group) </plain></SENT>
<SENT sid="5" pm="."><plain>Infusion was initiated 30 min before middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and continued for 24 h </plain></SENT>
<SENT sid="6" pm="."><plain>Additional rats received esmolol 50 microg x kg(-1) x min(-1) or landiolol 10 microg x kg(-1) x min(-1) intrathecally (IT) via the cisterna magna (n = 5 in each group), according to the same experimental protocol </plain></SENT>
<SENT sid="7" pm="."><plain>The neurological deficit score was evaluated at 22 h after reperfusion, and the brains were removed and stained with triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> for evaluation of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="8" pm="."><plain>Additional rats that received saline, esmolol, and landiolol IV (n = 6 in each group) were allowed to survive for 7 days followed by measurement of <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="9" pm="."><plain>Neurological deficit scores were smaller in rats treated with <z:chebi fb="2" ids="8499">propranolol</z:chebi>-IV, <z:chebi fb="0" ids="3441">carvedilol</z:chebi>-IV, esmolol-IV, landiolol-IV, esmolol-IT, and landiolol-IT compared with saline-treated rats (P &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>Cortical and striatum <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were less in the rats receiving beta-adrenoreceptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> via either IV or IT than in saline-treated rats (P &lt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that beta-adrenoreceptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> improve neurological and histological outcomes after transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats independent of administration route </plain></SENT>
</text></document>